🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06760000
Active, not recruiting Observational

S365: A Multicenter Longitudinal Cohort of Sleep Health

NCT06760000 · tracked via the Priya Life Science China tracker
Sponsor
Peking University
Phase
Observational
Started
2024-08-01
Last updated
2025-01-06

Condition(s) studied

Sleep DisorderSleep

Investigational drug(s) / intervention(s)

Five seasons Sleep Tracking Mat

Five seasons Sleep Tracking Mat: Non-contact mat monitoring sleep data through pulse wave detection

Study summary

The goal of this observational study is to explore the long-term health outcomes of sleep disorders in adults aged 18 and older, as well as to identify associated biomarkers and risk factors. The main questions it aims to answer are:

* What are the long-term health risks associated with sleep disorders, such as cognitive decline, cardiovascular diseases, or metabolic conditions?
* Are there specific biomarkers or patterns that can predict the onset or progression of sleep disorders?

Participants diagnosed with sleep disorders (e.g., insomnia, sleep apnea) or identified as healthy controls will undergo home-based sleep monitoring and complete clinical assessments at baseline and during follow-ups over a 3-year period. Biological samples, including blood and stool, will also be collected to analyze potential biomarkers. Data will be used to develop predictive models for sleep disorder risk and outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: * Willing to voluntarily participate in the study and provide signed informed consent. * Gender is not restricted, and baseline age is 18 years or older. * Experiencing sleep disorders and capable of complying with the study procedures and tests. Exclusion Criteria: * Diagnosed with severe mental health conditions, such as bipolar disorder, schizophrenia, or claustrophobia. * Suffering from infectious diseases, including tuberculosis, HIV/AIDS, or syphilis. * Pregnant women. * Experiencing acute inflammatory responses at the time of enrollment. * Long-term use of corticosteroids or undergoing hormone replacement therapy. * Determined by the researcher to be unsuitable for participation for any reason. * Patients with specific diseases (e.g., cardiovascular conditions) may be excluded if the study focuses on related comorbidities.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Institute of Medical Technology, Peking University Health Science Center Beijing Beijing Municipality

More Peking University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06760000 on ClinicalTrials.gov ↗ ← All trials in China